Andrew P. Han

Ex-CEO Roy Smythe is one of three people stepping down from the board. He will be replaced by Adam Taich, formerly executive VP of life sciences at SomaLogic.

Thermo Fisher Scientific's IonTorrent Genexus platform can provide cancer panel results in about a day, but data on clinical impact of the fast turnaround has not yet been produced.

In 2023, Thermo Fisher has laid off nearly 400 California employees at sites associated with Mesa Biotech, acquired in 2021 for $450 million in cash.

The proteomics firm is in talks to either spin off its SomaSignal assays unit or to partner with another company to boost its diagnostics efforts. 

The Marlborough, Massachusetts-based firm also announced new panels for its PhenoCycler-Fusion and PhenoImager HT spatial analysis platforms.  

The firm isn't planning a strategy for a kitted version of the test, though company officials said they were open to that in the future. 

The firm is also bringing its comprehensive genomic profiling assay for cancer to the Ion Torrent Genexus sequencing platform in the first half of 2023.

Labs should not let in silico data supplant physical specimens in bioinformatic validation and should understand the limitations of such data.

Separately, the US Federal Trade Commission said it will appeal an administrative law judge's initial decision in an antitrust case that was favorable to Illumina.

According to the firm, the judge "rejected the FTC's position that the deal would adversely affect competition" of multi-cancer early detection tests.